Phase 3 Eczema Trial, Completed

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 18 years old or older (note: in Korea, you must be 19 or older)
• You have been diagnosed with atopic dermatitis (eczema) using standard medical criteria
• You have had atopic dermatitis for at least 2 years
• Your atopic dermatitis has been rated as "moderate" by a doctor at both the screening visit and the start of the study (Day 1)
• Your eczema severity score is above a certain level at both the screening visit and Day 1 (confirm with trial site)
• Your itch level, rated on a scale, averages 4 or higher over the 7 days before Day 1, with at least 4 days of recorded scores
• Between 10% and 20% of your body surface area (not including the scalp) is affected by eczema at both the screening visit and Day 1
• Your quality of life is significantly affected by your eczema, as measured by a standard questionnaire score above 10
• In the past 12 months, standard prescription skin creams or ointments for eczema either did not work well enough for you, caused problems, or were not suitable for you
• You agree to stop using all other eczema treatments from the screening visit through to your final follow-up appointment, except those allowed by the study
• You agree to take steps to avoid becoming pregnant or causing a pregnancy during the study, as outlined by the study

Who may not be able to join:

• Your eczema has been getting significantly better or worse on its own in the 4 weeks before Day 1, as judged by the doctor
• You have a condition that weakens your immune system, such as lymphoma, AIDS, or certain rare immune disorders
• You have had a serious infection requiring prescription antibiotics, antivirals, or antifungal medicines taken by mouth or injection within 2 weeks before Day 1
• You have an active bacterial, fungal, or viral skin infection (such as cold sores, shingles, or chickenpox) within 1 week before Day 1
• You have another skin condition that could make it hard to assess your eczema or affect your safety, in the doctor's opinion
• Your eczema only affects your hands or feet, and you have no history of it affecting other typical areas like the face or skin folds
• You have had another type of eczema in the 6 months before screening (seborrheic dermatitis on the scalp is allowed)
• You have a current or past hepatitis B or C infection
• You have any serious illness — physical or mental — that, in the doctor's opinion, would prevent you from fully taking part in the study or put you at significant risk
• Your blood test results at screening show low hemoglobin (below 10 g/dL), poor liver function, poor kidney function, or a positive HIV test
• Any other blood test result that the doctor considers a significant health risk
• You have recently used certain medicines, including biologic injections, steroid tablets, immune-suppressing drugs, or strong CYP3A4 inhibitor medicines, without enough time having passed since stopping them (the required waiting period varies by medication — confirm with trial site)
• You have used certain topical (applied to skin) eczema treatments within 1 week before Day 1, such as steroid creams, calcineurin inhibitor creams, or antibiotic creams (plain moisturisers are allowed)
• You have previously tried a JAK inhibitor medicine (such as ruxolitinib, baricitinib, abrocitinib, or upadacitinib) for eczema or another inflammatory condition and it did not work
• You have had UV light therapy or significant sun or tanning bed exposure within 2 weeks before the start of the study, or you plan to during the study in a way that might affect your eczema
• You are currently taking part in another clinical trial or have taken an experimental medicine within the past 30 days or 5 half-lives of that medicine (whichever is longer)
• In the doctor's opinion, you are unlikely or unable to follow the study schedule, complete required diaries, or attend all required visits

Important: Always verify eligibility with the trial site directly before applying.